MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer
- PMID: 15475948
- DOI: 10.1038/nature03043
MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer
Abstract
Hepatocellular carcinoma is generally refractory to clinical treatment. Here, we report that inactivation of the MYC oncogene is sufficient to induce sustained regression of invasive liver cancers. MYC inactivation resulted en masse in tumour cells differentiating into hepatocytes and biliary cells forming bile duct structures, and this was associated with rapid loss of expression of the tumour marker alpha-fetoprotein, the increase in expression of liver cell markers cytokeratin 8 and carcinoembryonic antigen, and in some cells the liver stem cell marker cytokeratin 19. Using in vivo bioluminescence imaging we found that many of these tumour cells remained dormant as long as MYC remain inactivated; however, MYC reactivation immediately restored their neoplastic features. Using array comparative genomic hybridization we confirmed that these dormant liver cells and the restored tumour retained the identical molecular signature and hence were clonally derived from the tumour cells. Our results show how oncogene inactivation may reverse tumorigenesis in the most clinically difficult cancers. Oncogene inactivation uncovers the pluripotent capacity of tumours to differentiate into normal cellular lineages and tissue structures, while retaining their latent potential to become cancerous, and hence existing in a state of tumour dormancy.
Similar articles
-
Transforming growth factor-alpha inhibits the intrinsic pathway of c-Myc-induced apoptosis through activation of nuclear factor-kappaB in murine hepatocellular carcinomas.Mol Cancer Res. 2005 Jul;3(7):403-12. doi: 10.1158/1541-7786.MCR-04-0186. Mol Cancer Res. 2005. PMID: 16046551
-
Rehabilitation of cancer through oncogene inactivation.Trends Mol Med. 2005 Jul;11(7):316-21. doi: 10.1016/j.molmed.2005.05.003. Trends Mol Med. 2005. PMID: 15955741 Review.
-
Tumor dormancy and MYC inactivation: pushing cancer to the brink of normalcy.Cancer Res. 2005 Jun 1;65(11):4471-4. doi: 10.1158/0008-5472.CAN-05-1172. Cancer Res. 2005. PMID: 15930260 Review.
-
Brief inactivation of c-Myc is not sufficient for sustained regression of c-Myc-induced tumours of pancreatic islets and skin epidermis.BMC Biol. 2004 Dec 21;2:26. doi: 10.1186/1741-7007-2-26. BMC Biol. 2004. PMID: 15613240 Free PMC article.
-
Oncogene addiction: sometimes a temporary slavery.Cancer Cell. 2004 Dec;6(6):535-8. doi: 10.1016/j.ccr.2004.12.002. Cancer Cell. 2004. PMID: 15607957 Review.
Cited by
-
The Emerging Role of Ubiquitin-Specific Protease 36 (USP36) in Cancer and Beyond.Biomolecules. 2024 May 12;14(5):572. doi: 10.3390/biom14050572. Biomolecules. 2024. PMID: 38785979 Free PMC article. Review.
-
Tryptophan fuels MYC-dependent liver tumorigenesis through indole 3-pyruvate synthesis.Nat Commun. 2024 May 20;15(1):4266. doi: 10.1038/s41467-024-47868-3. Nat Commun. 2024. PMID: 38769298 Free PMC article.
-
New insights in ubiquitin-dependent Wnt receptor regulation in tumorigenesis.In Vitro Cell Dev Biol Anim. 2024 May;60(5):449-465. doi: 10.1007/s11626-024-00855-w. Epub 2024 Feb 21. In Vitro Cell Dev Biol Anim. 2024. PMID: 38383910 Free PMC article. Review.
-
Cooperativity of c-MYC with Krüppel-Like Factor 6 Splice Variant 1 induces phenotypic plasticity and promotes prostate cancer progression and metastasis.bioRxiv [Preprint]. 2024 Feb 1:2024.01.30.577982. doi: 10.1101/2024.01.30.577982. bioRxiv. 2024. PMID: 38352401 Free PMC article. Preprint.
-
Overexpression of deubiquitinase (usp 36) in oral squamous cell carcinoma.J Oral Maxillofac Pathol. 2023 Oct-Dec;27(4):623-628. doi: 10.4103/jomfp.jomfp_311_23. Epub 2023 Dec 20. J Oral Maxillofac Pathol. 2023. PMID: 38304515 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials